Effects of dimethyl fumarate on lymphocyte subsets

Multiple Sclerosis and Related Disorders

Volumn 4, Issue 4, 2015, Pages 339-341

  Berkovich, Regina ^a   Weiner, Leslie P ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Dimethyl fumarate; Lymphopenia; Multiple sclerosis

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA INTERFERON; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; METHYLPREDNISOLONE; NATALIZUMAB; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; BALANCE IMPAIRMENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELLULITIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONFUSION; DISEASE DURATION; DRUG EFFECT; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEMALE; HERPES SIMPLEX; HUMAN; LETHARGY; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOPENIA; MALE; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT DURATION; URINARY TRACT INFECTION; VIRUS ENCEPHALITIS; WEST NILE VIRUS; BLOOD; CASE REPORT; CHEMICALLY INDUCED; DRUG EFFECTS; FATALITY; FOLLOW UP; MIDDLE AGED; WEST NILE FEVER;

ADULT; DIMETHYL FUMARATE; FATAL OUTCOME; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; LYMPHOPENIA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES; WEST NILE FEVER;

EID: 84937436086     PISSN: 22110348     EISSN: 22110356     Source Type: Journal    
DOI: 10.1016/j.msard.2015.06.002     Document Type: Article

References (8)

1. Center for Disease Control and Prevention (CDC), 2015. West Nile Virus. Available at: (www.cdc.gov/westnile/index.html) (accessed 28.04.15).
2. Chaves, C.; Ganguly, R.; Dionne, C.; et al.; 2014. Safety and efficacy of dimethyl fumarate in patients with relapsing remitting MS (RRMS) in a community setting. Presented at the 2014 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the Sixth Cooperative Meeting with Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS). Dallas, TX (Abstract DX22)
3. R.J. Fox, D.H. Miller, J.T. Phillips, and et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis New Engl. J. Med. 367 12 2012 1087 1097
4. Fox, R.J.; Gold, R.; Phillips, J.T.; et al.; 2014. Lymphocyte count reductions in relapsing-remitting multiple sclerosis (RRMS) patients treated with delayed-release dimethyl fumarate: an integrated analysis of the placebo-controlled studies. Presented at the 66th Annual Meeting of the American Academy of Neurology. April 26-May 3, 2014
5. E.E. Longbrake, and A.H. Cross Dimethyl fumarate associated lymphopenia in clinical practice Mult Scler. 21 6 2015 796 797
6. L.R. Petersen, and A.A. Marfin West nile virus: a primer for the clinician Ann. Intern. Med. 137 2002 173 179
7. C.M. Spencer, E.C. Crabtree-Hartman, K. Lehmann-Horn, and et al. Reduction of CD8 T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate Neurol. Neuroimmunol. Neuroinflammation 2 3 2015 e76
8. Tecfidera (package insert), 2014. Biogen Idec, Cambridge, MA.